BURLINGTON, Mass. -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the

read more>>

NOVATO, Calif. -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment

read more>>

Oesophageal cancer rates in men have risen by 50 per cent over the last 25 years, according to new figures published by Cancer Research UK todayIn 1983 around 2,600 men were diagnosed with oesophageal cancer – cancer of the food pipe – and according to the latest figures around 5,100 m

read more>>

Under a massive expansion of its oncology services, Brazil’s national health care system (SUS) will offer cancer patients access to nine new treatments and expand coverage for 66 already-covered procedures, including 46 chemotherapy treatmentsThe nine treatments which are to be made availabl

read more>>

CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, GermanyThe milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-

read more>>

As of August 28, 2010, about 211 people, majority children, died attributed to the outbreak of Japanese encephalitis in the poor areas of Northern IndiaAccording to regional health officer U. K. Srivastaka, as of August 27, 2010, approximately 1,299 patients were admitted in hospitals in Gorakhpur

read more>>

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trialBoth the 7mg

read more>>

BOSTON -- Genzyme Corp (GENZ.O) said it will end rationing of the Gaucher disease drug Cerezyme for U.S. patients in September, a move it hopes will prove it is emerging from a manufacturing crisis that decimated its shares and helped make the company an acquisition targetThe Cambridge, Massachuse

read more>>

A partnership between the Cystinosis Research Foundation and the Cystinosis Foundation along with a collaboration of 12 advocate foundations from around the world has launched the first global cystinosis patient registryThe registry’s goal is to connect patients with researchers and others d

read more>>

Basel -- The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phaseTasigna is the first new therapeutic opti

read more>>